Cyclopharm (ASX:CYC) Inventories, Finished Goods : A$1.90 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm Inventories, Finished Goods?

Cyclopharm's quarterly finished goods declined from Dec. 2022 (A$1.69 Mil) to Jun. 2023 (A$0.00 Mil) but then increased from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$1.90 Mil).

Cyclopharm's annual finished goods declined from Dec. 2021 (A$1.69 Mil) to Dec. 2022 (A$1.69 Mil) but then increased from Dec. 2022 (A$1.69 Mil) to Dec. 2023 (A$1.90 Mil).

Cyclopharm Inventories, Finished Goods Historical Data

The historical data trend for Cyclopharm's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm Inventories, Finished Goods Chart

Cyclopharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

1.20

1.84

1.69

1.90

Cyclopharm Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Inventories, Finished Goods	Get a 7-Day Free Trial															1.69	-	1.69	-	1.90

Cyclopharm Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Cyclopharm (ASX:CYC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cyclopharm Ltd (ASX:CYC) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208

Website

https://cyclopharm.com.au

Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm (ASX:CYC) Headlines

No Headlines